secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001140361-24-045343
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore Q3 2024: KIMMTRAK revenue $80.2M (+28% YoY); EPS $0.17; CFO to depart
--------------------------------------------------------------------------------

- KIMMTRAK net revenue $80.2M in Q3 2024, up 28% vs $62.6M in Q3 2023; US $57.3M, Europe $21.0M.
- GAAP EPS $0.17 (diluted), net income $8.7M vs $0.9M in Q3 2023; cash $901.3M at Sept 30, 2024.
- CFO Brian Di Donato to leave end of 2024; search for replacement in progress.
- Brenetafusp (PRAME-A02) Phase 1 data at ESMO; NSCLC signal-detection shift delays initial data release.
- Plans to repay $50M loan by end of 2024; pay ~$40M in sales-related rebate accruals in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124045343/0001140361-24-045343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124045343/ef20038108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-045343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer